Compass Therapeutics (CMPX) Leases (2021 - 2026)

Compass Therapeutics' Leases history runs 6 years deep, the most recent figure standing at $8.7 million for Q1 2026.

• In Q1 2026, Leases rose 34.41% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (up 34.41% YoY), while the FY2025 annual figure was $9.1 million, up 35.18% from the prior year.
• Leases came in at $8.7 million for Q1 2026 at Compass Therapeutics, down from $9.1 million in the prior quarter.
• In the past five years, Leases ranged from a high of $9.8 million in Q2 2025 to a low of $1.2 million in Q2 2024.
• A 5-year average of $4.8 million and a median of $3.5 million in 2022 frame the typical range for Leases.
• Across the five-year window, Leases slumped 51.66% in 2024 and jumped 750.3% in 2025, its largest moves.
• Compass Therapeutics' Leases stood at $3.0 million in 2022, then plunged by 40.14% to $1.8 million in 2023, then surged by 279.0% to $6.7 million in 2024, then soared by 35.18% to $9.1 million in 2025, then declined by 3.88% to $8.7 million in 2026.
• According to Business Quant data, Leases over the past three periods registered $8.7 million, $9.1 million, and $9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison